Fibroid nonenhancement is considered a relative contraindication to uterine artery embolization (UAE) for symptomatic fibroids. This retrospective study assessed the impact of UAE on nonenhancing fibroids to determine imaging predictors of fibroid shrinkage. All women who underwent UAE for symptomatic fibroids between May 2009 and July 2014 and had followup magnetic resonance imaging 6 months after UAE were included. There were 59 fibroids (5 nonenhancing, 54 enhancing) among 18 women aged 40 to 53 (mean 46) years. All fibroids were assessed for size, position, and enhancement on subtraction and apparent diffusion constant (ADC) images. Enhancing fibroids had an average decrease in diameter of 19% ± 3%, not significantly different than nonenhancing fibroids, which decreased 23% ± 6% (P = 0.49). Multiple linear regression with percent change in fibroid diameter as the dependent variable and patient age, fibroid position, and pre-UAE fibroid diameter, enhancement, and ADC as independent variables showed that ADC (P = 0.04) and pre-UAE diameter (P = 0.03) were the only significant independent variables. In conclusion, pre-UAE size and ADC, but not contrast enhancement, predicted fibroid diameter reduction. Enhancing and nonenhancing fibroids had a similar size reduction after UAE. Nonenhancement should not be considered a contraindication to UAE. U terine artery embolization (UAE) is a minimally invasive treatment with the potential to decrease fi broid size and reduce symptoms (1) (2) (3) . Volume reduction after embolization is associated with decreased fi broid-related symptoms, such as pain and dysmenorrhea (4, 5) . Complete necrosis after UAE also predicts better long-term outcomes, with less pain and fi broid recurrence (4) . Th rough the use of magnetic resonance imaging (MRI), fi broids are readily identifi ed and monitored after UAE. Fibroids are typically hypointense on T2 and enhance following the intravenous administration of gadolinium due to ample blood supply (6) . Multiple papers have recommended that women with nonenhancing fi broids should be excluded from UAE due to anticipated minimal response in terms of size reduction (6-10), though there is a lack of studies directly comparing outcomes of enhancing vs nonenhancing fi broids. One retrospective study with 94 patients described the incidence of nonenhancing fi broids and recommended against their embolization, but did not report if the nonenhancing fi broids actually had poorer response (7) . For patients with un-resectable hepatocellular carcinoma, chemoembolization is still performed for hypovascular tumors, as there is evidence that a portion of these tumors do respond to embolization (11) . It is possible that nonenhancing fi broids respond similarly. Th e purpose of this study was to determine the response of necrotic fi broids to UAE and to identify whether pre-UAE enhancement or other factors are predictors of fi broid shrinkage.
METHODS
Th is retrospective study involved all women who underwent UAE for symptomatic fi broids between May 2009 and July 2014 with follow-up MRI 6 months after the procedure, identifi ed through a search of the departmental picture archiving and communication system. Th e mean follow-up period was 7.4 months. A total of 59 fi broids (5 nonenhancing, 54 enhancing) were analyzed in 18 patients ranging from 40 to 53 years of age with a mean age of 46 years. Fibroids analyzed ranged in size from 1.6 to 18.2 cm, with a mean diameter of 5.4 cm. Eightyfi ve other patients underwent UAE during this period, but did not have follow-up imaging and were therefore excluded.
UAE was performed as previously described (12) . Briefl y, procedures were performed with monitored anesthesia care. Access was obtained via the right common femoral artery, using a 5Fr introducer sheath (Cordis, Miami Lakes, FL); the anterior division of the internal iliac artery on each side was selected with a 5Fr guiding Cobra catheter (AngioDynamics, Latham, NY). A 2.8Fr ProGreat microcatheter (Terumo Interventional Systems, Somerset, NJ) was then directed into each uterine artery. Embolization was performed with 500 to 700 micron Embospheres (BioSphere Medical, Rockland, MA) until antegrade fl ow stasis. A completion perirenal aortogram was performed to exclude ovarian artery supply to the uterus. Patients were admitted for at least one night of observation.
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Next, multiple linear regression was performed with percent change in fi broid diameter as the dependent variable and patient age, fi broid location (subserosal, submucosal, or intramural), pre-UAE fi broid diameter, enhancement, and ADC as independent variables. Only ADC (P = 0.04) and pre-UAE diameter (P = 0.03) were signifi cant independent variables; smaller diameter and higher ADC were associated with greater decreases in size. For example, fi broids with a pre-UAE diameter greater than the median (48.9 mm) decreased in diameter by 15%, whereas fi broids with a pre-UAE diameter less than the median decreased in diameter by 25% (P = 0.05). In contrast, pre-UAE enhancement was not an independent predictor of post-UAE size diminution (P = 0.31).
DISCUSSION
Th is study demonstrates that nonenhancing fi broids have a decrease in size similar to that of enhancing fi broids after UAE. Furthermore, contrast enhancement on MRI did not predict changes in fi broid size, suggesting that patients with minimally enhancing and nonenhancing fi broids may still benefi t from UAE. Currently, there is confl icting data in the literature regarding fibroid enhancement as a predictor of UAE response. For instance, T1-and T2-weighted MR images were obtained with and without gadolinium contrast enhancement within 2 months before UAE and at 6 months after UAE. For each fi broid, pre-and post-UAE size was determined by measuring the widest diameter on T2-weighted imaging. All fi broids measuring at least 2 cm were assessed for each patient. Fibroids were classifi ed by position as either submucosal, intramural, or subserosal. Th e T1-weighted signal intensity of each fi broid was recorded on dynamic contrast-enhanced subtraction MRI by placing a circular region of interest (ROI) over the axial or coronal slice with the largest crosssectional area. Additionally, fi broids were characterized as nonenhancing or enhancing by subjective comparison of the fi broid to the myometrium on postcontrast images. Apparent diff usion constant (ADC) was determined for each pre-UAE fi broid with a corresponding ROI.
Statistical analysis was performed using GraphPad Prism 6. Comparisons were made using paired Student t tests when variables were normally distributed and Mann-Whitney tests when variables were not normally distributed. A P < 0.05 was considered statistically signifi cant. Percent fi broid enhancement pre-UAE was calculated by dividing the fi broid signal intensity by myometrial signal intensity on contrast-enhanced T1-weighted imaging. Multiple linear regression was used to determine if fi broid enhancement, ADC value, fi broid size, fi broid location (intramural, subserosal, submucosal), and patient age were independent predictors of fi broid shrinkage after UAE. Data are presented as mean ± standard error of the mean.
RESULTS
A total of 59 fi broids were assessed, 39 (66%) of which were intramural. ADC was, on average, 708.5 ± 74.2 × 10 6 mm 2 /s. Mean diameter was 53.6 ± 3.9 mm before UAE and 44.0 ± 3.7 mm after UAE. Mean enhancement on subtraction MRI was 127.0 ± 15.5 SI before UAE and 3.9 ± 0.5 SI after UAE.
Overall, fi broids decreased in diameter by 20% ± 3%. Fifteen of the fi broids were nonenhancing. Th ese fi broids decreased one study of 28 fi broids reported that avidly enhancing fi broids had greater volume reduction (8) . Other studies reported to the contrary that greater enhancement pre-UAE does not necessarily predict better response (13) (14) (15) . One study did not fi nd a greater volume reduction 4 months post-UAE between 14 fi broids that were well perfused compared with 21 fi broids that were not well perfused (13) . More recently, a study of 182 patients reported that low vascularity might predict a more favorable outcome in patients treated with embolization; it was found that patients with lower-vascularity fi broids had a lower incidence of recurrence than patients with higher-vascularity fi broids (14) . Additionally, avidly enhancing fi broids rapidly decreased in size shortly after embolization but plateaued after 6 months, as opposed to less-enhancing fi broids that continued to shrink after 6 months (14) . Th is may explain why previous studies with a shorter follow-up period reported greater volume reduction in enhancing fi broids (8, 9) . Our study adds to this literature by showing that nonenhancing and presumably necrotic fi broids respond to UAE, despite their relative avascularity. Th erefore, women with necrotic fi broids should not be excluded from treatment. Th ough one may assume that embolization should be more eff ective for fi broids of greater vascularity, fi broids have particularly abnormal angiogenesis and vascularization patterns that are not completely understood. Th e avascular and hypoxic environment of fi broids is paradoxically associated with more proangiogenic factors (16) .
Our fi ndings also suggest that ADC is an independent predictor of fi broid shrinkage. Fibroids with higher ADC values pre-UAE demonstrated greater shrinkage, which has been reported in other retrospective and prospective investigations (9, 15, 17) . It is unclear what the degree of diff usion restriction of water molecules signifi es, but ADC provides some information about the molecular and/or cellular composition of masses including fi broids, and it may be useful in pre-UAE patient selection. We also found that smaller fi broid size predicted greater reduction after UAE, which is in contrast to other studies that showed either no correlation between fi broid size and volume reduction (18) or better response in larger fi broids (8) .
Th e primary limitations of this study pertain to its singlecenter retrospective nature. Our primary marker of UAE response was restricted to fi broid size instead of clinical outcomes due to limited data availability in our medical database. Th e length of follow-up was also limited due to the practice of obtaining MRI imaging 6 months after embolization without the need for longer-term imaging. A longer-term prospective study with a larger sample size and clinical correlates could therefore increase the accuracy of our evaluations and help prove that patients with minimally or nonenhancing fi broids can still benefi t from embolization. In addition to fi broid size reduction on imaging, clinical markers such as bleeding, pain, and recurrence could also be measured. Fibroid size is a more objective marker, refl ects data easier to collect, and is generally associated with symptom improvement, but clinical markers will more accurately predict response (4, 5) .
In conclusion, nonenhancing fi broids respond to UAE, particularly in regard to size reduction. In addition, MRI characteristics such as ADC values may better predict response to UAE. Especially for women who either do not desire surgery or want to preserve fertility, UAE may be the best option, and it is important not to withhold therapy without clear evidence of its ineffi cacy in the setting of nonenhancement. Th ese results suggest that physicians should reconsider excluding women with nonenhancing fi broids, as these patients may also benefi t from emboliza tion.
